Leonie Saft

About me
Publications
CV
Public outreach and news

About me

I am a senior consultant in clinical pathology and team leader of the division of Hematopathology and Flow Cytometry at Karolinska University Laboratory (KUL), Solna. I studied medicine in Germany (Philipps University Marburg, 1988/89
J.W. Goethe University, Frankfurt, 1989–1994) and in the USA (University of Texas Medical Branch, UTMB, Galveston, Texas, 1994–95), earning both German and American medical degrees. I obtained my doctoral degree in 1996 at J.W. Goethe University in Frankfurt with a dissertation on nosocomial Aspergillus infections. After a period of clinical work in hematology/oncology (Klinikum Darmstadt, Germany), I performed my specialist training in Clinical Pathology (Leipzig, 1997–98
Uppsala, 1999–2001
and since 2001 Karolinska University Hospital) and became specialist in 2003 with subspecializations in neuro-oncopathology and hematopathology.

Research

Following my PhD studies at Karolinska Institute, Huddinge (2008-2013) and thesis defence (2013) on Myelodysplastic syndrome (MDS) (supervisor: Prof. Eva Hellström-Lindberg), I participated as a reference pathologist in several clinical trials by the Nordic MDS Group. In addition, I became involved in International Multicenter Studies (European Leuk Net MDS Flow Working Group) to explore the role of flow cytometry in unexplained cytopenias and suspected MDS. I am currently engaged in clinical research projects with other units at Karolinska University Laboratory, focusing on the molecular characterization of lymphoma and
acute pediatric leukemias as part of Genomic Medicine Sweden (GMS). Additionally, I am local PI in a bilateral research project aiming at identifying potential precursor stages of lymphoma in lymphoid tissues. I also lead a research project on the development of AI-based tools in bone marrow diagnostics for implementation in routine diagnostics (Clinical Fellowship 2022–2024, CIMV, Linköping University).

Teaching

Since 2001, I have been teaching at both the undergraduate and graduate levels at Karolinska Institutet. I have served as course leader for specialist training courses and have participated as a teacher in international courses. Since 2024, I am visiting professor at Semmelweis University in Budapest, teaching in the medical program.

Articles

Journal article: PRECISION ONCOGENOMICS. 2024;1(1):1-7
Overcoming Brigatinib Resistance with Lorlatinib in Pediatric ALK Positive Anaplastic Large Cell Lymphoma with Acquired ALK p.F1174V Mutation – a Case Report
Wessman S; Mogensen N; Ranta S; Saft L; von Bahr Greenwood T; Tesi B; De Ståhl TD; Baecklund F
Article: PATHOLOGIE. 2023;44(3):164-175
The role of flow cytometry in the classification of myeloid disorders
Saft L
Article: CYTOMETRY. PART A : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR ANALYTICAL CYTOLOGY. 2023;104(1):87-97
A series of case studies illustrating the role of flow cytometry in the diagnostic work-up of myelodysplastic syndromes
Westers TM; Saft L; van der Velden VHJ; te Marvelde JG; Dunlop A; Ireland R; Valent P; Porwit A; Bene MC; van de Loosdrecht AA
Article: CYTOMETRY. PART A : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR ANALYTICAL CYTOLOGY. 2023;104(1):77-86
Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group
Loosdrecht AA; Kern W; Porwit A; Valent P; Kordasti S; Cremers E; Alhan C; Duetz C; Dunlop A; Hobo W; Preijers F; Wagner-Ballon O; Chapuis N; Fontenay M; Bettelheim P; Eidenschink-Brodersen L; Font P; Johansson U; Loken MR; Marvelde JG; Matarraz S; Ogata K; Oelschlaegel U; Orfao A; Psarra K; Subira D; Wells DA; Bene MC; Della Porta MG; Burbury K; Bellos F; van der Velden VHJ; Westers TM; Saft L; Ireland R
Article: CYTOMETRY. PART A : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR ANALYTICAL CYTOLOGY. 2023;104(1):15-26
Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet
van der Velden VHJ; Preijers F; Johansson U; Westers TM; Dunlop A; Porwit A; Bene MC; Valent P; te Marvelde J; Wagner-Ballon O; Oelschlaegel U; Saft L; Kordasti S; Ireland R; Cremers E; Alhan C; Duetz C; Hobo W; Chapuis N; Fontenay M; Bettelheim P; Eidenshink-Brodersen L; Font P; Loken MR; Matarraz S; Ogata K; Orfao A; Psarra K; Subira D; Wells DA; Della Porta MG; Burbury K; Bellos F; Weiss E; Kern W; van de Loosdrecht A
Article: CYTOMETRY. PART A : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR ANALYTICAL CYTOLOGY. 2023;104(1):51-65
Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group
Kern W; Westers TM; Bellos F; Bene MC; Bettelheim P; Brodersen LE; Burbury K; Chu S-C; Cullen M; Della Porta M; Dunlop AS; Johansson U; Matarraz S; Oelschlaegel U; Ogata K; Porwit A; Preijers F; Psarra K; Saft L; Subira D; Weiss E; van der Velden VHJ; van de Loosdrecht A
Article: JOURNAL OF INTERNAL MEDICINE. 2022;292(6):925-940
Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial
Jadersten M; Lilienthal I; Tsesmetzis N; Lourda M; Bengtzen S; Bohlin A; Arnroth C; Erkers T; Seashore-Ludlow B; Giraud G; Barkhordar GS; Tao S; Fogelstrand L; Saft L; Ostling P; Schinazi RF; Kim B; Schaller T; Juliusson G; Deneberg S; Lehmann S; Rassidakis GZ; Hoglund M; Henter J-I; Herold N
Journal article: HEMASPHERE. 2022;6:442-443
P543: TARGETING SAMHD1 WITH HYDROXYUREA IN FIRST‐LINE CYTARABINE‐BASED THERAPY OF NEWLY DIAGNOSED ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE HEAT‐AML TRIAL
Jädersten M; Lilienthal I; Tsesmetzis N; Lourda M; Bengtzén S; Bohlin A; Arnroth C; Erkers T; Seashore‐Ludlow B; Giraud G; Barkhordar GS; Tao S; Fogelstrand L; Saft L; Östling P; Schinazi R; Kim B; Schaller T; Juliusson G; Deneberg S; Lehmann S; Rassidakis G; Höglund M; Henter J; Herold N
Article: FRONTIERS IN ONCOLOGY. 2022;12:899325
Patient-Specific Assays Based on Whole-Genome Sequencing Data to Measure Residual Disease in Children With Acute Lymphoblastic Leukemia: A Proof of Concept Study
Arthur C; Rezayee F; Mogensen N; Saft L; Rosenquist R; Nordenskjold M; Harila-Saari A; Tham E; Barbany G
Article: FRONTIERS IN PEDIATRICS. 2022;10:1082986
Case Report: Whole genome sequencing identifies CCDC88C as a novel JAK2 fusion partner in pediatric T-cell acute lymphoblastic leukemia
Krstic A; Rezayee F; Saft L; Hammarsjoe A; Svenberg P; Barbany G
Article: JOURNAL OF HEMATOPATHOLOGY. 2020;13(2):79-88
Enumeration of CD34+blasts by immunohistochemistry in bone marrow biopsies from MDS patients may have significant impact on final WHO classification
Saft L; Timar B; Porwit A
Article: CYTOMETRY. PART A : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR ANALYTICAL CYTOLOGY. 2020;98(3):250-258
The diagnostic and prognostic role of flow cytometry in idiopathic and clonal cytopenia of undetermined significance (ICUS/CCUS): A single-center analysis of 79 patients
Dinnopoulos K; Hansen OK; Sjo LD; Saft L; Schjodt IM; Hansen JW; Gronbaek K
Article: LEUKEMIA AND LYMPHOMA. 2020;61(3):604-613
Overexpression of chromatin remodeling and tyrosine kinase genes in iAMP21-positive acute lymphoblastic leukemia
Ivanov Ofverholm I; Zachariadis V; Taylan F; Marincevic-Zuniga Y; Anh NT; Saft L; Nilsson D; Syvanen A-C; Lonnerholm G; Harila-Saari A; Nordenskjold M; Heyman M; Nordgren A; Nordlund J; Barbany G
Article: LEUKEMIA RESEARCH. 2018;71:75-81
Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+cells
Ogata K; Sei K; Saft L; Kawahara N; Della Porta MG; Chapuis N; Yamamoto Y
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2018;180(4):526-533
Megakaryocytes harbour the del(5q) abnormality despite complete clinical and cytogenetic remission induced by lenalidomide treatment
Scharenberg C; Jansson M; Saft L; Hellstrom-Lindberg E
Article: BLOOD. 2017;130(7):881-890
SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells
Mortera-Blanco T; Dimitriou M; Woll PS; Karimi M; Elvarsdottir E; Conte S; Tobiasson M; Jansson M; Douagi I; Moarii M; Saft L; Papaemmanuil E; Jacobsen SEW; Hellstrom-Lindberg E
Article: ANNALS OF HEMATOLOGY. 2017;96(7):1105-1112
Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance
de Swart L; Smith A; MacKenzie M; Symeonidis A; Neukirchen J; Mikulenkova D; Vallespi T; Zini G; Paszkowska-Kowalewska M; Kruger A; Saft L; Fenaux P; Bowen D; Hellstrom-Lindberg E; Cermak J; Stauder R; Tatic A; Holm MS; Malcovati L; Madry K; Droste J; Blijlevens N; de Witte T; Germing U
Article: HAEMATOLOGICA. 2017;102(3):498-508
Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations
Scharenberg C; Giai V; Pellagatti A; Saft L; Dimitriou M; Jansson M; Jadersten M; Grandien A; Douagi I; Neuberg DS; LeBlanc K; Boultwood J; Karimi M; Jacobsen SEW; Woll PS; Hellstrom-Lindberg E
Article: HAEMATOLOGICA. 2017;102(2):308-319
Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group
Westers TM; Cremers EMP; Oelschlaegel U; Johansson U; Bettelheim P; Matarraz S; Orfao A; Moshaver B; Brodersen LE; Loken MR; Wells DA; Subira D; Cullen M; Marvelde JGT; van der Velden VHJ; Preijers FWMB; Chu S-C; Feuillard J; Guderin E; Psarra K; Porwit A; Saft L; Ireland R; Milne T; Bene MC; Witte BI; Della Porta MG; Kern W; van De Loosdrecht AA
Journal article: BLOOD. 2016;128(22):4329
Progression in Patients with with Low- and Intermediate-1 Risk Del(5q) MDS Is Predicted By a Limited Subset of Mutations
Scharenberg C; Woll PS; Giai V; Pellagatti A; Saft L; Dimitriou M; Jädersten M; Jansson M; Douagi I; Neuberg DS; Karimi M; Le Blanc K; Boultwood J; Jacobsen SE; Hellstrom-Lindberg E
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2016;91(12):1234-1238
Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes
Hansen JW; Westman MK; Sjo LD; Saft L; Kristensen LS; Orskov AD; Treppendahl M; Andersen MK; Gronbaek K
Article: ANNALS OF HEMATOLOGY. 2016;95(11):1825-1832
TERT rs2736100 genotypes are associated with differential risk of myeloproliferative neoplasms in Swedish and Chinese male patient populations
Dahlstrom J; Liu T; Yuan X; Saft L; Ghaderi M; Wei YB; Lavebratt C; Li P; Zheng C; Bjorkholm M; Xu D
Article: PEDIATRIC BLOOD AND CANCER. 2015;62(6):951-956
Detection of Central Nervous System Involvement in Childhood Acute Lymphoblastic Leukemia by Cytomorphology and Flow Cytometry of the Cerebrospinal Fluid
Ranta S; Nilsson F; Harila-Saari A; Saft L; Tani E; Soderhall S; Porwit A; Hultdin M; Noren-Nystrom U; Heyman M
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2014;80(6):424-431
Dendritic Cells in Bone Marrow at Diagnosis and after Chemotherapy in Adult Patients with Acute Myeloid Leukaemia
Derolf AR; Laane E; Bjorklund E; Saft L; Bjorkholm M; Porwit A
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2014;93(5):439-445
A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine
Svensson T; Chowdhury O; Garelius H; Lorenz F; Saft L; Jacobsen S-E; Hellstrom-Lindberg E; Cherif H
Article: ONCOSCIENCE. 2014;1(8):550-557
Perturbations of the endocannabinoid system in mantle cell lymphoma: correlations to clinical and pathological features.
Wasik AM; Nygren L; Almestrand S; Zong F; Flygare J; Wennerholm SB; Saft L; Andersson P; Kimby E; Wahlin BE; Christensson B; Sander B
Article: HAEMATOLOGICA. 2014;99(6):1041-1049
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)
Saft L; Karimi M; Ghaderi M; Matolcsy A; Mufti GJ; Kulasekararaj A; Goehring G; Giagounidis A; Selleslag D; Muus P; Sanz G; Mittelman M; Bowen D; Porwit A; Fu T; Backstrom J; Fenaux P; MacBeth KJ; Hellstrom-Lindberg E
Article: BLOOD CANCER JOURNAL. 2014;4(3):e189
Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial
Tobiasson M; Dybedahl I; Holm MS; Karimi M; Brandefors L; Garelius H; Grovdal M; Hogh-Dufva I; Gronbaek K; Jansson M; Marcher C; Nilsson L; Kittang AO; Porwit A; Saft L; Mollgard L; Hellstrom-Lindberg E
Article: LEUKEMIA RESEARCH. 2013;37(3):266-273
Bone marrow dendritic cells are reduced in patients with high-risk myelodysplastic syndromes
Saft L; Bjorklund E; Berg E; Hellstrom-Lindberg E; Porwit A
Article: HAEMATOLOGICA. 2012;97(8):1209-1217
Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study
Della Porta MG; Picone C; Pascutto C; Malcovati L; Tamura H; Handa H; Czader M; Freeman S; Vyas P; Porwit A; Saft L; Westers TM; Alhan C; Cali C; van de Loosdrecht AA; Ogata K
Journal article: BLOOD. 2011;118(21):3798
Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome,
Tobiasson M; Brandefors L; Dybedal I; Garelius H; Grövdal M; Dufva IH; Kjeldsen L; Nilsson L; Kittang AO; Porwit A; Saft L; Holm MS; Möllgård L; Hellström-Lindberg E
Journal article: BLOOD. 2011;118(21):790
Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
Scharenberg C; Giai V; Pellagatti A; Saft L; Karlsson G; Jansson M; Forsblom L; Jadersten M; Karlsson S; Boultwood J; Hellstrom-Lindberg E
Article: HAEMATOLOGICA. 2011;96(7):963-971
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities
Mollgard L; Saft L; Treppendahl MB; Dybedal I; Norgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jadersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Gronbaek K; Lindberg EH
Journal article: JOURNAL OF HEMATOPATHOLOGY. 2011;4(2):69-79
The AML–MDS interface—leukemic transformation in myelodysplastic syndromes
Porwit A; Saft L
Article: JOURNAL OF CLINICAL ONCOLOGY. 2011;29(15):1971-1979
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Jaedersten M; Saft L; Smith A; Kulasekararaj A; Pomplun S; Goehring G; Hedlund A; Hast R; Schlegelberger B; Porwit A; Hellstrom-Lindberg E; Mufti GJ
Journal article: LEUKEMIA RESEARCH. 2011;35:s52
135 Lower bone marrow myeloid and plasmacytoid dendritic cell counts in high-risk than in low-risk MDS patients and controls
Saft L; Björklund E; Hellström-Lindberg E; Porwit A
Article: HAEMATOLOGICA. 2009;94(12):1762-1766
Clonal heterogeneity in the 5q-syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
Jadersten M; Saft L; Pellagatti A; Goehring G; Wainscoat JS; Boultwood J; Porwit A; Schlegelberger B; Hellstrom-Lindberg E
Journal article: BLOOD. 2008;112(11):5104
Clonal Heterogeneity in the 5q- Syndrome: NPMc+ and p53 Expressing Progenitors Are Insensitive to Lenalidomide Treatment and Expand at Disease Progression
Jädersten M; Saft L; Pellagatti A; Göhring G; Fernández-Santamaria C; Wainscoat JS; Boultwood J; Porwit A; Schlegelberger B; Hellström-Lindberg E
Article: ANTICANCER RESEARCH. 2006;26(6C):4895-4899
Reliability of the reported size of removed colorectal polyps
Rubio CA; Grimelius L; Lindholm J; Hamberg H; Porwit A; Elmberger G; Hoog A; Kanter L; Eriksson E; Stemme S; Orrego A; Saft L; Petersson F; De la Torre M; Ekstrom C; Astrom K; Rundgren A; Djokic M; Chandanos E; Lenander C; Machado M; Nilsson P; Mattsson L
Show more

All other publications

Review: HISTOPATHOLOGY. 2023;83(6):829-849
Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes: A workshop report with focus on novel entities and a literature review including paediatric cases
Saft L; Kvasnicka HM; Boudova L; Gianelli U; Lazzi S; Rozman M
Letter: ACTA ONCOLOGICA. 2023;62(6):560-564
The BioLymph study - implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results
Smedby KE; Waesterlid T; Tham E; Haider Z; Joelsson J; Thorvaldsdottir B; Krstic A; Wahlin BE; Foroughi-Asl H; Karlsson C; Eloranta S; Saft L; Palma M; Kwiecinska A; Hansson L; Osterborg A; Wirta V; Rassidakis G; Sander B; Sonnevi K; Rosenquist R
Review: CYTOMETRY. PART A : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR ANALYTICAL CYTOLOGY. 2023;104(1):27-50
Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group
Porwit A; Bene MC; Duetz C; Matarraz S; Oelschlaegel U; Westers TM; Wagner-Ballon O; Kordasti S; Valent P; Preijers F; Alhan C; Bellos F; Bettelheim P; Burbury K; Chapuis N; Cremers E; Della Porta MG; Dunlop A; Eidenschink-Brodersen L; Font P; Fontenay M; Hobo W; Ireland R; Johansson U; Loken MR; Ogata K; Orfao A; Psarra K; Saft L; Subira D; te Marvelde J; Wells DA; van der Velden VHJ; Kern W; van de Loosdrecht AA
Letter: ACTA ONCOLOGICA. 2022;61(7):824-829
Outcome in PCNSL patients and its association with PD-L1+leukocytes in the tumor microenvironment
Abdulla M; Hollander P; Lindskog C; Sundstrom C; Enblad G; Saft L; Amini R-M
Letter: LEUKEMIA. 2022;36(5):1436-1439
"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"
Rasmussen B; Gohring G; Bernard E; Nilsson L; Tobiasson M; Jadersten M; Garelius H; Dybedal I; Gronbaek K; Ejerblad E; Lorenz F; Flogegard M; Marcher CW; oster Fernstrom A; Cavelier L; Papaemmanuil E; Ebeling F; Kittang AO; Norgaard JM; Saft L; Mollgard L; Hellstrom-Lindberg E
Preprint: RESEARCH SQUARE. 2022
Patient-specific assays based on whole-genome sequencing data to measure residual disease in children with acute lymphoblastic leukemia – a proof-of- concept study
Arthur C; Rezayee F; Mogensen N; Saft L; Rosenquist R; Nordenskjöld M; Harila-Saari A; Tham E; Barbany G
Review: JOURNAL OF HEMATOPATHOLOGY. 2022;15(1):13-19
Intracerebral manifestation of iatrogenic, immunodeficiency-associated polymorphic B-LPD with morphology mimicking Hodgkin lymphoma: a case report and literature review
Saft L; Perdiki-Grigoriadi M; Rassidakis G
Conference publication: BLOOD. 2021;138:3995
Multicenter Prospective Evaluation of Diagnostic Potential of Flow Cytometric Aberrancies in Myelodysplastic Syndromes
Kern W; Westers TM; Bellos F; Bene MC; Bettelheim P; Brodersen LE; Burbury K; Chu S-C; Cullen M; Della Porta M; Dunlop AS; Johansson U; Matarraz S; Oelschlaegel U; Ogata K; Porwit A; Preijers FWMB; Psarra K; Saft L; Subira D; Weiss E; Van de Loosdrecht AA
Review: AMERICAN JOURNAL OF CLINICAL PATHOLOGY. 2021;155(2):179-210
Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders Report of the 2019 Society for Hematopathology/European Association for Haematopathology Workshop
Kelemen K; Saft L; Craig FE; Orazi A; Nakashima M; Wertheim GB; George TI; Horny H-P; King RL; Quintanilla-Martinez L; Wang SA; Rimsza LM; Reichard KK
Published conference paper: PATHOBIOLOGY. 2019;86(1):62-75
Challenges in Diagnosing Myelodysplastic Syndromes in the Era of Genetic Testing: Proceedings of the 13th Workshop of the European Bone Marrow Working Group
Hebeda KM; Tzankov A; Boudova L; Saft L; Hasserjian RP; de Boer M; Fend F; Orazi A; Leguit R
Conference publication: BLOOD. 2018;132:794
From Mild Cytopenia to Overt MDS and AML, the Mutational Profile Predicts Progression, but Not Survival
Hansen JW; Johansen MM; Westman MK; Saft L; Sjo LD; Marcher CW; Holm MS; Dimitriou M; Karimi M; Raaschou-Jensen K; Glenthoj AB; Severinsen MT; Hellstrom-Lindberg E; Andersen MK; Gronbaek K
Conference publication: BLOOD. 2018;132:3105
The Diagnostic Role of Flow Cytometry in Idiopathic Cytopenia of Unknown Significance (ICUS): A Single-Center Analysis of 79 Patients
Dimopoulos K; Hansen OK; Hansen JW; Sjo L; Saft L; Gronbaek K
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2018;180(5):744-748
CD274 (PD-L1)/PDCD1 (PD-1) expression in de novo and transformed diffuse large B-cell lymphoma
Kwiecinska A; Tsesmetzis N; Ghaderi M; Kis L; Saft L; Rassidakis GZ
Conference publication: HAEMATOLOGICA. 2017;102:183
PATIENTS WITH IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE SHOW SIMILAR SURVIVAL PATTERNS AS LOW RISK MDS PATIENTS
Hansen JW; Westman M; Orskov AD; Sjo L; Saft L; Holm MS; Marcher CC; Karimi M; Hellstrom-Lindberg E; Andersen MK; Gronbaek K
Conference publication: HAEMATOLOGICA. 2016;101:74-75
FREQUENT MUTATIONS IN EPIGENETIC REGULATORS IN CYTOPENIA OF UNDETERMINED SIGNIFICANCE: ASSOCIATION WITH RISK OF PROGRESSION TO MYELODYSPLASTIC SYNDROME
Hansen JW; Westman MK; Sjo LD; Saft L; Kristensen LS; Orskov AD; Treppendahl M; Andersen MK; Gronbaek K
Conference publication: BLOOD. 2014;124(21):414
p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study
Saft L; Li JS; Greenberg PL; Sekeres MA; Sanz GF; Dreyfus F; Fenaux P; Swern AS; Sugrue MM; Hellstrom-Lindberg E
Conference publication: HAEMATOLOGICA. 2014;99:688
PERTURBATIONS OF THE ENDOCANNABINOID SYSTEM IN MANTLE CELL LYMPHOMA; CORRELATIONS TO CLINICAL AND PATHOLOGICAL FEATURES
Wasik A; Nygren L; Almestrand S; Zong F; Flygare J; Wennerholm SB; Saft L; Andersson P; Kimby E; Christensson B; Sander B
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2014;80(3):237-238
Perturbations of the Endocannabinoid System in Mantle Cell Lymphoma; Correlations to Clinical and Pathological Features
Wasik AM; Nygren L; Almestrand S; Zong F; Flygare J; Baumgartner-Wennerholm S; Saft L; Andersson P; Kimby E; Christensson B; Sander B
Conference publication: HAEMATOLOGICA. 2014;99:695
RAPID TRANSFORMATION OF FOLLICULAR LYMPHOMA, GRADE 1, ASSOCIATED WITH AN UNCOMMON C.796G>A PG266R MUTATION OF THE P53 GENE AND LOSS OF CD45 (LCA) EXPRESSION AT DIAGNOSIS
Kwiecinska A; Ghaderi M; Xagoraris I; Matolcsy A; Saft L; Otsterborg A; Rassidakis G
Conference publication: LEUKEMIA RESEARCH. 2013;37:S66
p53 protein expression predicts outcome and cytogenetic response in patients with low-/INT-1-risk myelodysplastic syndromes treated with lenalidomide
Saft L; Karimi M; Ghaderi M; Matolscy A; Fenaux P; Mufti G; Giagounidis A; Selleslag D; Muus P; Sanz G; Mittelman M; Bowen D; Porwit A; Fu T; Backstrom J; MacBeth K; Hellstrom-Lindberg E
Thesis / dissertation: 2013
TP53 mutations in myelodysplastic syndromes with deletion of 5q
Saft, Leonie
Conference publication: HAEMATOLOGICA. 2013;98:483
P53 PROTEIN EXPRESSION PREDICTS OUTCOME AND CYTOGENETIC RESPONSE IN PATIENTS WITH LOW-/INT-1 RISK MYELODYSPLASTIC SYNDROMES TREATED WITH LENALIDOMIDE: RESULTS FROM THE MDS004 CLINICAL TRIAL.
Saft L; Karimi M; Ghaderi M; Matolscy A; Fenaux P; Mufti G; Giagounidis A; Selleslag D; Muus P; Sanz G; Mittelman M; Bowen D; Porwit A; Fu T; Backstrom J; MacBeth K; Hellstrom-Lindberg E
Conference publication: HAEMATOLOGICA. 2013;98:251
A PILOT PHASE ONE DOSE FINDING SAFETY STUDY OF A THROMBOPOIETIN-RECEPTOR AGONIST, ELTROMBOPAG, IN PATIENTS WITH MYELODYSPLASTIC SYNDROME TREATED WITH AZACITIDINE
Svensson T; Garelius H; Lorenz F; Saft L; Hellstrom-Lindberg E; Cherif H
Conference publication: HAEMATOLOGICA. 2012;97:140-141
EVALUATION OF AZACITIDINE IN TRANSFUSION-DEPENDENT, EPO-REFRACTORY PATIENTS WITH LOWER-RISK MDS
Tobiasson M; Brandefors L; Dybedahl I; Garelius H; Grovdal M; Hogh-Dufva I; Kjeldsen L; Marcher C; Nilsson L; Kittang AO; Porwit A; Saft L; Holm MS; Mollgard L; Hellstrom-Lindberg E
Conference publication: BLOOD. 2011;118(21):1622-1623
Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome
Tobiasson M; Brandefors L; Dybedal I; Garelius H; Grovdal M; Dufva IH; Kjeldsen L; Nilsson L; Kittang AO; Porwit A; Saft L; Holm MS; Mollgard L; Hellstrom-Lindberg E
Conference publication: BLOOD. 2011;118(21):359
Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
Scharenberg C; Giai V; Pellagatti A; Saft L; Karlsson G; Jansson M; Forsblom L; Jadersten M; Karlsson S; Boultwood J; Hellstrom-Lindberg E
Conference publication: CYTOMETRY. PART A : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR ANALYTICAL CYTOLOGY. 2011;79A(12):1051-1052
MULTICENTRE VALIDATION OF A REPRODUCIBLE FLOW CYTOMETRIC SCORE FOR THE DIAGNOSIS OF LOWRISK MYELODYSPLASTIC SYNDROMES: RESULTS OF A EUROPEAN LeukemiaNET STUDY
Picone C; Tenore A; Vanelli L; Malcovati L; Pascutto C; Ogata K; Tamura H; Handa H; Czader M; Freeman S; Vyas P; Porwit A; Saft L; Westers TM; Alhan C; Cali C; van de Loosdrecht AA; Cazzola M; Della Porta MG
Conference publication: HAEMATOLOGICA. 2010;95:126
DETECTION OF TP53 MUTATIONS IN LOW-RISK MYELODYSPLASTIC SYNDROMES WITH DEL(5Q) IS ASSOCIATED WITH DISEASE PROGRESSION
Jadersten M; Saft L; Smith A; Kulasekararaj A; Pomplun S; Hast R; Porwit A; Hellstrom-Lindberg E; Mufti G
Meeting abstract: LEUKEMIA RESEARCH. 2009;33:S39
Expression of p53 or cytoplasmic nucleophosmine associated with increased risk of disease progression in myelodysplastic syndrome with isolated del(5q)
Jadersten M; Saft L; Garelius H; Hast R; Nilsson L; Samuelsson J; Porwit A; Hellstrom-Lindberg E
Conference publication: HAEMATOLOGICA. 2009;94:102
EXPRESSION OF P53 OR CYTOPLASMIC NUCLEOPHOSMINE ASSOCIATED WITH INCREASED RISK OF DISEASE PROGRESSION IN MYELODYSPLASTIC SYNDROME WITH ISOLATED DEL(5Q)
Jadersten MS; Saft L; Garelius H; Hast R; Nilsson L; Samuelsson J; Porwit A; Hellstrom-Lindberg E
Show more

Employments

Affiliated to Research, Department of Oncology-Pathology, Karolinska Institutet, 2023-2026
Clinical Assistant, Department of Oncology-Pathology, Karolinska Institutet, 2024-2024

Degrees and Education

Degree Of Doctor Of Philosophy, Department of Medicine, Huddinge, Karolinska Institutet, 2013

About me

Research

Teaching

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI